Clinical trials have demonstrated weight loss ranging from approximately 10% with GLP-1 agents at weight management doses (e.g., semaglutide 2.4 mg in the STEP trials) to over 20% with tirzepatide at higher doses (SURMOUNT trials)
Barry cautions
BPC-157 works through angiogenesis via VEGFR2, nitric oxide synthesis, growth hormone receptor upregulation, and ERK1/2 signaling
[1] [2] Documentation of injection site reactions, including photographs when appropriate, can help clinicians assess severity and progression
Foods to avoid High-fat foods, particularly fried foods and fatty animal products, significantly worsen GI side effects on tirzepatide
How GLP-1 Medications Fit into Modern Obesity and Menopause Care GLP-1 receptor agonists, medications like Ozempic, Wegovy, and Mounjaro , were developed over two decades ago for type 2 diabetes